Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) reported on Thursday that it had received ethics approval from a central institutional review board for US study sites for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for COVID-19
. Ifenprodil is an NMDA receptor antagonist specifically targeting the NMDA-type subunit 2B.
To learn more about this work,
click here.
AGN also recently received ethics approval from the
Royal Brisbane & Women’s Hospital, Human Research Ethics Committee for its Phase 2 Idiopathic Pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (
Ifenprodil).
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.